hotspot -WSS

hotspot

author：explore 2025-09-30 00:49:45 - browse：67346

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Impact of Dobbs ruling felt at reproductive medicine meeting

hotspot

WSS

Mass General, Mayo Clinic look to monetize custom

FDA warns J&J's Abiomed: We will regulate your software

First Opinion Podcast: Long Covid needs a new approach

STAT Summit: Biotech founders on deal

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

STAT Summit: Michael J. Fox on progress in Parkinson's research

entertainment

hotspot

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Immunocompromised patients offer clues on chronic Covid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Impact of Dobbs ruling felt at reproductive medicine meeting

Guidelines to prevent youth baseball injuries need more muscle

FDA endorses new sterilization method for medical devices

Sports medicine is finally prioritizing gender equality

STAT Summit: GSK CEO on pharma giant's new direction

Jerome Adams on the need for new antivirals for Covid

Cardiologists urge adding sexual orientation, gender identity to health records

knowledge

CVS is on a mission to consolidate health care. Will it work?

Senate committee scrutinizes Medicare Advantage brokers

UnitedHealth’s board chair also owns a personal investment firm

Prior authorization reform is both possible and imperative

Immunocompromised patients offer clues on chronic Covid

STAT Summit: Biotech founders on deal

entertainment

hotspot

hotspot

explore